In this issue, Weinstein and colleagues provide evidence demonstrating the cost–benefit of resistance testing in patients
with HIV infection. However, further virologic, clinical, and quality-adjusted life-year data should be obtained before therapeutic
drug monitoring is implemented in routine practice.